Early recurrence risk: aromatase inhibitors versus tamoxifen.

Abstract:

:Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy and safety of initial adjuvant therapy with letrozole or anastrozole versus the previous standard of 5 years of adjuvant tamoxifen and support using an AI (exemestane, anastrozole or letrozole) following tamoxifen for 2-3 years (early 'switch' treatment) or 5 years (extended adjuvant treatment). Reducing recurrence risk is a primary goal of adjuvant hormonal therapy. There is an early peak of recurrences 2 years after surgery; most are distant metastases rather than local or regional events. Therefore, treatment strategies such as initial therapy with AIs, which reduce early distant recurrence events, can be expected to improve long-term survival outcomes. Switching to an AI following 2-3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI.

authors

Bria E,Carlini P,Cuppone F,Vaccaro V,Milella M,Cognetti F

doi

10.1586/era.10.54

subject

Has Abstract

pub_date

2010-08-01 00:00:00

pages

1239-53

issue

8

eissn

1473-7140

issn

1744-8328

journal_volume

10

pub_type

杂志文章,评审
  • Colorectal cancer: using blood samples and tumor tissue to detect K-ras mutations.

    abstract::We performed a meta-analysis to assess whether blood can be substituted for tumor tissue in K-ras mutation testing. PubMed, EMBASE, MEDLINE, and BIOSIS databases were searched. Twenty-three studies including 1261 patients were included. The pooled overall sensitivity, specificity, and concordance rate were 0.69 (95% C...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,meta分析

    doi:10.1586/14737140.2015.1037836

    authors: Li Y,Fu XH,Yuan JQ,Yang ZY,Mao C,Dong XM,Tang JL,Wang SY

    更新日期:2015-06-01 00:00:00

  • Surgical management of pediatric brain tumors.

    abstract::Brain tumors are the most common cause of cancer-related death and the second most common form of cancer in pediatric patients. Many of these tumors are treated primarily with surgery, either alone or in combination with radiation or chemotherapy. Recent advances have lead to greater survival and decreased morbidities...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.12s.S61

    authors: Heuer GG,Jackson EM,Magge SN,Storm PB

    更新日期:2007-12-01 00:00:00

  • Early outcomes data for accelerated partial breast irradiation using balloon brachytherapy.

    abstract::Accelerated partial breast irradiation has been investigated in selected patients with early-stage breast cancer. Accelerated partial breast irradiation limits the radiation target to the volume of tissue immediately surrounding the lumpectomy cavity and reduces the overall treatment time from approximately 6 weeks to...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.113

    authors: Cuttino LW,Vicini FA

    更新日期:2011-09-01 00:00:00

  • The role of surgery in recurrent endometrial cancer.

    abstract:INTRODUCTION:Endometrial cancer is a common gynecologic malignancy in the United States, and the recurrence rate depends on the disease stage at diagnosis. Recurrence can affect several areas and follow different patterns. AREAS COVERED:The role of surgery at the time of recurrence is not clearly defined. In this revi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2016.1190650

    authors: Zanfagnin V,Ferrero A,Biglia N,Aletti G,Gill SE,Makdisi PB,Multinu F,Mariani A

    更新日期:2016-07-01 00:00:00

  • Breath testing as a method for detecting lung cancer.

    abstract::Early diagnosis of lung cancer is important due to high mortality in late stages of the disease. An ideal approach for population screening could be the breath analysis, due to its non-invasiveness, simplicity and cheapness. Using sensitive methods of analysis like gas chromatography/mass spectrometry in exhaled air o...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/14737140.2014.866044

    authors: Taivans I,Bukovskis M,Strazda G,Jurka N

    更新日期:2013-12-13 00:00:00

  • Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.

    abstract:INTRODUCTION:The aim of this paper was to perform a narrative review of the literature on the available approaches in the treatment of two emerging subpopulations of metastatic renal cell carcinoma (mRCC) patients: the oligometastatic disease (less than 5 metastasis) and the oligoprogressive disease, defined as worseni...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1770601

    authors: Donini M,Buti S,Massari F,Mollica V,Rizzo A,Montironi R,Bersanelli M,Santoni M

    更新日期:2020-06-01 00:00:00

  • Management of advanced bladder cancer in patients with impaired renal function.

    abstract::Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of these patients and is considered the standard of care. Nevertheless, 40-50% of patients have impaired renal function that p...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.10.197

    authors: Bournakis E,Dimopoulos MA,Bamias A

    更新日期:2011-06-01 00:00:00

  • Prostate-sparing cystectomy: has Pandora's box been opened?

    abstract::En bloc removal of the prostate has traditionally been an integral component of radical cystectomy for men with bladder cancer owing to a high incidence of occult prostatic malignancy. However, the risk of functional morbidity following this procedure is considerable and can delay patient acceptance of cystectomy, whi...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.7.1003

    authors: Kefer JC,Cherullo EE,Jones JS,Gong MC,Campbell SC

    更新日期:2007-07-01 00:00:00

  • Antineoplastic therapy-induced pulmonary toxicity.

    abstract::Pulmonary complications of antineoplastic therapy are common and are an important cause of respiratory morbidity. The pulmonary toxicity should be taken into account in every patient with respiratory problems who is or has been treated with antineoplastic agents. The diagnosis of drug-induced pulmonary toxicity is com...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2013.817684

    authors: Sadowska AM,Specenier P,Germonpre P,Peeters M

    更新日期:2013-08-01 00:00:00

  • Molecular markers of chemotherapeutic response and toxicity in colorectal cancer.

    abstract::Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of new and effective chemotherapeutic agents, such as irinotecan and oxaliplatin. However, not all patients respond to these agents and a proportion may suffer se...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.7.4.489

    authors: Braun MS,Quirke P,Seymour MT

    更新日期:2007-04-01 00:00:00

  • Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action.

    abstract::Novel targeted agents, such as VEGF receptor-tyrosine kinase inhibitors (VEGFR-TKIs) and mTOR inhibitors, have improved therapy for metastatic renal cell carcinoma. Sequential administration of agents with similar mechanisms of action has shown some efficacy in small retrospective studies; however, prospective Phase I...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.21

    authors: Larkin J,Swanton C,Pickering L

    更新日期:2011-04-01 00:00:00

  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review.

    abstract::Primary systemic therapy (PST) in early breast cancer is utilized in locally advanced breast tumors and when breast-conserving surgery is desirable. In addition, the PST setting provides an opportunity to monitor response including histopathological and biomarker examination of the tumor and host tissues before and af...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.12.62

    authors: Khasraw M,Bell R

    更新日期:2012-08-01 00:00:00

  • Ixabepilone: a new microtubule-targeting agent for breast cancer.

    abstract::Results of clinical trials over the past 15 years demonstrate that the taxanes are among the most effective new class of cytotoxic drugs to treat breast cancer and other solid tumors. Moreover, the efficacy of the taxanes added further credence to the relevance of the microtubule as a tumor target. In spite of the sig...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.5.671

    authors: Higa GM,Abraham J

    更新日期:2008-05-01 00:00:00

  • Role of FDG-PET in the diagnosis and management of lung cancer.

    abstract::Positron emission tomography (PET) using [(18)F]-2-deoxy-2-fluoro-d-glucose (FDG) has emerged as a valuable diagnostic modality in patients with non-small cell lung cancer (NSCLC). Data in the literature show that the addition of FDG-PET definitely alters clinical management in patients with potentially resectable NSC...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.4.4.561

    authors: Oyen WJ,Bussink J,Verhagen AF,Corstens FH,Bootsma GP

    更新日期:2004-08-01 00:00:00

  • Immunotherapy for renal cell cancer in the era of targeted therapy.

    abstract::Until recently, cytokine therapy has been the only validated option for patients with advanced renal cancer. IFN-alpha is one of very few treatments that have demonstrated improved median survival compared with the appropriate control. In patients with synchronous metastases at diagnosis, debulking nephrectomy prior t...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.6.907

    authors: Coppin C

    更新日期:2008-06-01 00:00:00

  • Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract.

    abstract:INTRODUCTION:To date, all efforts to fight gastrointestinal cancer, regardless of its origin and entity, have resulted in complex therapeutic regimens involving a combination of systemic therapy, radiation therapy and surgery. It is generally accepted across all disciplines that not one, but the combination and the pro...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1868991

    authors: Neumann PA,Berlet MW,Friess H

    更新日期:2021-01-08 00:00:00

  • End points for Phase II trials in recurrent glioblastoma: the cornerstone for a new era.

    abstract::In recent years, novel approaches have been developed in medical oncology, and antiangiogenic treatments have had a role in the treatment of colorectal, renal and breast cancers. The role of these agents in brain tumors is, however, controversial, since these drugs may induce modifications in neuroradiological pattern...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/era.11.164

    authors: Franceschi E,Agati R,Brandes AA

    更新日期:2011-11-01 00:00:00

  • Recent advances in the management of squamous cell carcinoma of the head and neck.

    abstract::Therapeutic outcomes of the currently used chemotherapeutic agents for recurrent or advanced head and neck squamous cell carcinoma, such as methotrexate or a combination of 5-fluorouracil and cisplatin, are far beyond satisfaction. New chemotherapeutic agents, such as taxanes, paclitaxel and docetaxel, are among the m...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.1.1.99

    authors: Kim KB,Khuri FR,Shin DM

    更新日期:2001-06-01 00:00:00

  • Treatment of childhood acute myeloid leukemia.

    abstract::Childhood acute myeloid leukemia is rare, but accounts for a significant number of malignancy-related deaths in this age group. However, the prognosis has improved over past decades, and survival rates of 60% and above have been reported. Still, this implies that more than a third of children and adolescents die from ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.5.917

    authors: ter Bals E,Kaspers GJ

    更新日期:2005-10-01 00:00:00

  • Targeted therapy for metastatic colorectal cancer.

    abstract:INTRODUCTION:Outcomes in metastatic colorectal cancer are improving, with better understanding and use of targeted therapies. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This article reviews the current ...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1502664

    authors: Price TJ,Tang M,Gibbs P,Haller DG,Peeters M,Arnold D,Segelov E,Roy A,Tebbutt N,Pavlakis N,Karapetis C,Burge M,Shapiro J

    更新日期:2018-10-01 00:00:00

  • Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?

    abstract::Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis. In addition, limited active therapeutic options are available. The cytotoxic drug gemcitabine and the inhibition of the mTOR pathway have demonstrated modest activity in sarcomas as monotherapy. However, prec...

    journal_title:Expert review of anticancer therapy

    pub_type: 社论

    doi:10.1586/14737140.2015.1003045

    authors: Martin-Liberal J,Tirado OM,García del Muro X

    更新日期:2015-03-01 00:00:00

  • Nivolumab for the treatment of colorectal cancer.

    abstract:INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1080/14737140.2018.1480942

    authors: Smith KM,Desai J

    更新日期:2018-07-01 00:00:00

  • Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.

    abstract::Until now, no effective systemic treatment options have been available for patients with unresectable advanced hepatocellular carcinoma (HCC). In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP), patients with unresectable advanced HCC with Child-Pugh liver function class A and who had not...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1586/era.09.41

    authors: Rimassa L,Santoro A

    更新日期:2009-06-01 00:00:00

  • 5th Canadian Melanoma Conference: research frontiers.

    abstract::The prospects for the treatment of metastatic melanoma are improving. Whereas previous scientific meetings dedicated to the treatment of metastatic melanoma patients were overshadowed by our inability to improve overall survival or lengthen the time to progression, the results presented at the most recent meetings are...

    journal_title:Expert review of anticancer therapy

    pub_type:

    doi:10.1586/era.11.62

    authors: van Kempen LC

    更新日期:2011-06-01 00:00:00

  • Clodronate in the prevention and treatment of skeletal metastasis.

    abstract::Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.5.2.221

    authors: Gulley J,Dahut WL

    更新日期:2005-04-01 00:00:00

  • Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.

    abstract:INTRODUCTION:Metastatic prostate cancer is a life-threatening disease and an important public health concern with prevalence rates varying drastically between high- and low-income countries. Androgen-deprivation therapy alone has been the first-line treatment option for decades, temporarily controlling disease until in...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2020.1785289

    authors: Manceau C,Mourey L,Pouessel D,Ploussard G

    更新日期:2020-08-01 00:00:00

  • Organ preservation strategies in bladder cancer.

    abstract::Bladder cancer is a significant cause of morbidity and mortality. Promising results with organ preservation strategies using multimodality treatment over the last decade offers an option for bladder preservation in a significant proportion of patients who currently undergo cystectomy. The primary goal of the bladder-s...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2.6.641

    authors: Hussain SA,James ND

    更新日期:2002-12-01 00:00:00

  • Current concepts and future strategies in the management of intracranial germinoma.

    abstract::Radiation therapy is the backbone in the management of intracranial germinoma. In localized disease chemotherapy followed by whole brain irradiation is the present standard providing cure rates in excess of 90%. Craniospinal irradiation alone in metastatic disease provides equally excellent outcome. Chemotherapy is ab...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.2014.856268

    authors: Kortmann RD

    更新日期:2014-01-01 00:00:00

  • Current surgical treatment of intermediate risk differentiated thyroid cancer: a systematic review.

    abstract::Introduction: Surgical treatment of thyroid cancer has become less aggressive but for many patients, the threshold for performing total thyroidectomy (TT), as opposed to thyroid lobectomy (TL), has remained unclear. Current American Thyroid Association (ATA) guidelines encourage more individualization of treatment opt...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章

    doi:10.1080/14737140.2021.1850280

    authors: Guo MY,Wiseman JJ,Wiseman SM

    更新日期:2020-12-15 00:00:00

  • Docetaxel in the treatment of advanced non-small-cell lung cancer.

    abstract::Systemic chemotherapy provides improvement in both survival and quality of life for patients with advanced non-small-cell lung cancer (NSCLC). Docetaxel is the only agent currently approved for both first- and second-line treatment of advanced NSCLC. Multiple randomized clinical trials have established the efficacy of...

    journal_title:Expert review of anticancer therapy

    pub_type: 杂志文章,评审

    doi:10.1586/14737140.8.8.1207

    authors: Saloustros E,Georgoulias V

    更新日期:2008-08-01 00:00:00